All In Biotech

Drug Trial Radar · NCT07141329

SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures

An Open-Label Extension, One-Year, Safety, and Efficacy Study of SPN-817 in Adults With Focal Onset Seizures

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 30, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Supernus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.

Conditions

  • Focal Onset Seizures

Interventions

  • SPN-817Drug

    SPN-817 starting at 0.25 mg bid up to 4.00 mg bid

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse eventsTime frame: Week 1-Week 52

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Center for Neurosciences

    Tucson, Arizona

  • Focus Clinical Research

    West Hills, California

  • Ilumina Medical Research

    Kissimmee, Florida

  • Medsol Clinical Research Center

    Port Charlotte, Florida

  • University of Rochester Medical Center

    Rochester, New York

  • Asheville Neurology Specialists

    Asheville, North Carolina

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • The Alfred Hospital

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.